Literature DB >> 26247350

Bayesian methods for the design and analysis of noninferiority trials.

Margaret Gamalo-Siebers1, Aijun Gao2, Mani Lakshminarayanan3, Guanghan Liu4, Fanni Natanegara5, Radha Railkar3, Heinz Schmidli6, Guochen Song7.   

Abstract

The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.

Keywords:  Bayesian inference; clinical trial; meta-analysis; noninferiority

Mesh:

Substances:

Year:  2015        PMID: 26247350     DOI: 10.1080/10543406.2015.1074920

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

1.  Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor.

Authors:  Wenqing Li; Ming-Hui Chen; Xiaojing Wangy; Dipak K Dey
Journal:  Stat Biosci       Date:  2017-07-06

2.  A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results.

Authors:  Don van Ravenzwaaij; John P A Ioannidis
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

3.  A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events.

Authors:  Camille Aupiais; Corinne Alberti; Thomas Schmitz; Olivier Baud; Moreno Ursino; Sarah Zohar
Journal:  BMC Med Res Methodol       Date:  2019-09-18       Impact factor: 4.615

4.  Optimising a multi-strategy implementation intervention to improve the delivery of a school physical activity policy at scale: findings from a randomised noninferiority trial.

Authors:  Cassandra Lane; Luke Wolfenden; Alix Hall; Rachel Sutherland; Patti-Jean Naylor; Chris Oldmeadow; Lucy Leigh; Adam Shoesmith; Adrian Bauman; Nicole McCarthy; Nicole Nathan
Journal:  Int J Behav Nutr Phys Act       Date:  2022-08-20       Impact factor: 8.915

5.  Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors:  Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal:  Clin Lung Cancer       Date:  2020-06-05       Impact factor: 4.785

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.